The process of neurodegeneration in Parkinson's disease begins long before the onset of clinical motor symptoms, resulting in substantial cell loss by the time a diagnosis can be made. The period between the onset of neurodegeneration and the development of motoric disease would be the ideal time to intervene with disease modifying therapies. This pre-motor phase can last many years, but the lack of a specific clinical phenotype means that objective biomarkers are needed to reliably detect prodromal disease. In recent years, recognition that patients with REM sleep behaviour disorder (RBD) are at particularly high risk of future parkinsonism has enabled the development of large prodromal cohorts in which to investigate novel biomarkers, and neuroimaging has generated some of the most promising results to date. Here we review investigations undertaken in RBD and other preclinical cohorts, including modalities that are well established in clinical Parkinson's as well as novel imaging methods. Techniques such as high resolution MRI of the substantia nigra and functional imaging of Parkinsonian brain networks have great potential to facilitate early diagnosis. Further longitudinal studies will establish their true value in quantifying prodromal neurodegeneration and predicting future Parkinson's.
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Introduction
Parkinson's Disease is currently diagnosed when the cardinal motor sign of bradykinesia appears alongside rigidity, tremor or postural instability 1 . These features are caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta and consequent denervation of the dorsal striatum 2 . The pathological hallmark of the disease is the presence of Lewy bodies within these structures, containing intracellular aggregations of misfolded alphasynuclein. The anatomical origin of the disease process, however, is likely to be further afield, perhaps even outside of the brain 3, 4 . Braak's hypothesis suggests that neurodegeneration is initiated in the lower brainstem and anterior olfactory structures before ascending to the basal ganglia and cortical areas in a characteristic sequence. In keeping with this, non-motor symptoms such as hyposmia, autonomic failure and sleep disturbances commonly emerge many years before motor parkinsonism 5 . The importance of developing reliable methods for diagnosis during this pre-motor phase is underlined by the observation that more than 50% of nigral dopaminergic neurons and up to 80% of nigrostriatal synaptic activity have been lost by the time the motor phenotype emerges 6, 7 . In the face of such extensive, irreversible neurodegeneration it may be too late to substantially alter the disease course with neuroprotective agents. However, whilst the constellation of prodromal symptoms in Parkinson's is well described, most features, for example depression and constipation, are non-specific 8 ; even those with the highest predictive value for future disease development, such as REM sleep behaviour disorder, leave many questions unanswered regarding an individual's trajectory.
In recent years the terms pre-clinical and prodromal have been used to describe the period between the onset of neurodegeneration and the development of diagnostic motor signs, with pre-clinical referring to the asymptomatic phase and prodromal describing the emergence of non-motor symptoms as the disease progresses 9 . Just as the natural history of established Parkinson's encompasses a broad spectrum of disease phenotypes, so the rate of progression through the pre-clinical and prodromal phases is likely to be highly variable.
Post-mortem and neuroimaging studies suggest that degeneration within the basal ganglia may commence up to 7 years prior to diagnosis 10, 11 , but prodromal symptoms such as hyposmia and REM sleep behaviour disorder can emerge decades earlier in some cases 12, 13 .
The potential window of opportunity that this creates for early therapeutic interventions
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4 has led to extensive research activity in search of biomarkers that can reliably detect Parkinson's during this period.
The ideal diagnostic imaging test would not only confirm the presence of prodromal Parkinson's but also give some information about the lead time to motoric disease and the rate of progression. This inevitably means that long term follow-up will be required before such tests can be validated against the gold standard of clinical diagnosis. Sensitivity to longitudinal change may provide a surrogate imaging marker and demonstration of this in serial assessments would be a valuable characteristic. Reproducibility is crucial as any neuroprotective trials are likely to require multi-site involvement to recruit sufficient numbers of prodromal subjects 14 . Finally, any imaging test to enter mainstream clinical practice must be cost efficient and widely available.
Pre-clinical and prodromal cohorts
When selecting populations in whom to investigate pre-motor neuroimaging tests, a balance must be struck between cohorts that are truly representative of idiopathic Parkinson's as a whole and cohorts that are sufficiently enriched for at-risk individuals to enable adequate numbers of positive results to be obtained. Population wide screening may capture the full spectrum of sporadic disease in its pre-clinical and prodromal phases, but is generally not feasible for neuroimaging studies when the outcome of interest is relatively rare. Narrowing down such cohorts by selecting for prodromal features or family history can overcome this problem, but only by selecting for a particular subtype of disease in whom findings may not be wholly generalizable.
Asymptomatic carriers of mutations that cause rare, monogenic forms of Parkinson's present the only opportunity to study a highly enriched cohort in the pre-clinical (rather than prodromal) phase. The most common monogenic cause of Parkinson's is mutation of the autosomal dominant Leucine Rich Repeat Kinase (LRRK2) gene 15 , and families harbouring LRRK2 mutations have been the subject of many neuroimaging studies.
However, the incomplete penetrance of this mutation, ranging from 24 -74% by age 80 in various study populations [16] [17] [18] , means that long term follow-up is still necessary to confirm true pre-clinical subjects. There is also evidence that the characteristics of the prodromal phase in genetic forms of Parkinson's vary according to the gene concerned, calling into
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5 question the generalizability of these findings to sporadic disease [19] [20] [21] . Heterozygous carriers of genes causing recessive forms of Parkinson's have also been studied, but the risk of Parkinson's in these subjects is low and the form of Parkinson's seen in homozygotes exhibits a different pattern of neurodegeneration to sporadic disease and is therefore even less representative 22, 23 . The size of genetic cohorts is also a limitation as large numbers of subjects are likely to be needed to power neuroprotective trials. 12, 32 . There remains a need for tests that can provide information regarding lead time and progression of prodromal neurodegeneration.
6 Whilst most prodromal neuroimaging research has been conducted in RBD cohorts, studying RBD is not without limitations. Firstly, we cannot yet predict which alphasynucleinopathy these patients will develop in future. This may not matter if the objective is to treat with an agent that targets a common molecular pathway, such as monoclonal antibodies against alpha-synuclein. Furthermore, some promising imaging biomarkers may themselves shed light on the ultimate disease phenotype. A second limitation is that Parkinson's patients who develop RBD in the prodromal phase may represent a particular subtype of disease, with an akinetic-rigid motor phenotype and more severe non-motor symptoms such as depression, autonomic failure and cognitive impairment 30, 31 .
Neuroimaging studies in established Parkinson's support this, with evidence of more widespread degeneration in Parkinson's patients with concomitant RBD 34, 35 . Finally, a male to female ratio of around 5:1 is typically seen in idiopathic RBD, compared with 2:1 in Parkinson's. Whether RBD is truly distributed in this pattern or simply more likely to be reported in men, the underrepresentation of women in these cohorts is a significant source of bias. Despite these limitations, imaging studies in RBD have generated some of the most promising prodromal biomarkers to date.
Neuroimaging in pre-motor Parkinson's.
Development of a diagnostic imaging test for pre-clinical or prodromal Parkinson's is a significant challenge given that such a test has so far failed to supplant clinical diagnosis in established Parkinson's. However, recent expansion in the number of prodromal cohorts under investigation and the development of novel imaging techniques make this a rapidly advancing field with great near-term potential. This review will focus predominantly on those studies with diagnostic and prognostic potential for prodromal Parkinson's in general, rather than studies devoted to mechanisms of pathogenesis, phenotypic variation or cohortspecific factors, though these will be covered briefly when relevant. The wide range of imaging modalities that has been investigated can be broadly divided into three approaches:
1) those that target dopaminergic function in the basal ganglia 2) those that directly image the substantia nigra and 3) those assessing perturbations of disease-related brain networks.
Dopaminergic radiotracer imaging
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7 Assessment of the integrity of dopaminergic circuits in the basal ganglia can be made using a range of radio-labelled ligands, detected with single photon emission computed tomography (SPECT) or positron emission tomography (PET) 36 . The most frequently labelled structure with SPECT is the presynaptic dopamine transporter (DAT), which is responsible for re-uptake of dopamine from the synaptic cleft by the pre-synaptic nerve terminal.
Visualisation of this structure with 123 I-FP-CIT (ioflupane) SPECT is currently the only imaging method to be approved by the Food and Drug Administration (FDA, United States) and the National Institute for Health and Care Excellence (NICE, United Kingdom) for the differentiation of parkinsonian syndromes from other causes of tremor. In this regard it can separate cases of parkinsonism from essential tremor with sensitivity of 95% and specificity of 93% 37 , and consistently demonstrates greater specificity than clinical examination in diagnostically uncertain cases 38, 39 .
PET has been used with various radio-labelled ligands to interrogate aspects of dopaminergic transmission in the basal ganglia 36, 40 . The presynaptic dopamine transporter (DAT) can be targeted with compounds such as 18 F-FP-CIT, 11 C-methylphenidate ( 11 C-MP) or 18 F-FE-PE2I 41 . The intracellular vesicular monoamine transporter (VMAT2) is responsible for re-packaging dopamine into vesicles, and is commonly labelled with 11 Cdihydrotetrabenazine ( 11 C-DTBZ) or 18F-fluoropropyl-dihydrotetrabenazine (18F-FP-DTBZ). 18 F-DOPA is taken up by neurons in the same manner as L-DOPA, where it is a substrate for dopa decarboxylase; imaging this compound therefore reflects the brain's capacity to take up, process and store dopamine. Finally, ligands such as 11C-raclopride or 18F-fallypride can be used to measure binding to the post-synaptic dopamine D2 and D3 receptor, as can the SPECT compound 123 I-IBZM (iodobenzamide).
The presynaptic DAT signal is depressed in the posterior putamen early in the course of Parkinson's disease and demonstrates characteristic asymmetry in the pattern of signal loss 42 . The level of striatal DAT binding in PD correlates with contralateral clinical measures of bradykinesia and rigidity 43 , as well as with the degree of dopaminergic cell loss in the substantia nigra post-mortem 44 . It is sensitive to longitudinal changes, demonstrating a significantly faster rate of decline in patients with Parkinson's than in healthy controls 45, 46 , although this must be interpreted with caution in the context of treatment with medications that might themselves lead to downregulation of DAT levels 36 . This potential confounding
8 effect of medication is avoided when studying pre-motor Parkinson's, and the fact that substantial nigro-striatal cell loss occurs before the onset of motor symptoms makes dopaminergic radiotracer imaging an attractive modality to evaluate preclinical and prodromal disease. A major disadvantage of both PET and SPECT, however, is the exposure of subjects to ionising radiation. This is a particular limitation in younger subjects and in serial longitudinal studies where the cumulative risk of repeated scans may be unacceptable.
Dopaminergic imaging in hyposmic cohorts
Several studies using SPECT have demonstrated pathologically reduced DAT signal in a proportion of people with idiopathic hyposmia [47] [48] [49] Parkinson's and these subjects had substantially faster decline in the DAT signal on serial imaging than hyposmic non-converters 50 . Further follow-up will establish the true predictive value of DAT SPECT in these subjects, but this already demonstrates substantial enrichment for a population-ascertained cohort. However, given the low overall incidence of PD in this group, identification of clinical features that can further risk stratify subjects prior to imaging will be important for future studies.
Dopaminergic imaging in REM Sleep Behaviour Disorder (RBD) cohorts
Early studies using PET and SPECT to image presynaptic and vesicular dopamine transporters in RBD confirmed that a deficit is detectable in these patients 51, 52 , and
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9 subsequent larger cohorts comparing RBD subjects to healthy controls have demonstrated that around 20-40% of RBD patients have abnormal DAT imaging [53] [54] [55] . The DAT deficit seen in RBD is less severe than in established Parkinson's 56, 57 , suggesting that dopaminergic imaging may have the potential to quantify progression through the prodromal phase. The presence of subtle motor abnormalities in RBD subjects is more predictive of a DAT deficit than hyposmia 58, 59 , consistent with longitudinal studies in RBD showing that motor signs occur late in the prodromal phase whereas olfaction is lost early 60 . Reduced F-DOPA uptake in the putamen has also been reported in a single study of 11 RBD patients with concurrent major depressive disorder 61 .
In one of the largest studies using DAT SPECT, Iranzo and colleagues found pathologically reduced 123 
Dopaminergic imaging in genetic cohorts
The use of dopaminergic imaging as a pre-clinical biomarker in asymptomatic LRRK2 carriers has yielded some elegant results. In a cross-sectional study of a large Spanish cohort, DAT SPECT revealed pathologically reduced striatal uptake in 43.7% of 32 asymptomatic carriers 63 . This figure closely matches the observed penetrance of the mutation and it will be interesting to see from longitudinal follow-up whether these individuals are indeed those who go on to develop clinical disease.
The use of three different PET ligands in a study of two North American kindreds revealed a pattern of progressive neurodegeneration in asymptomatic LRRK2 carriers that provides insight into the mechanism of pathogenesis at different pre-motor stages 64 . Out of six asymptomatic carriers, all had normal F-DOPA uptake; four had abnormal DAT signal
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10 measured by 11 C-MP, and two of these subjects had abnormal VMAT2 levels, measured by 11 C-DTBZ. At follow-up after 2.5 years one of these two subjects had converted to clinical Parkinson's, and this was accompanied by the development of abnormal F-DOPA uptake 65 .
This intriguing result mirrors the changes seen in early Parkinson's, where compensatory mechanisms downregulate presynaptic DAT in the already reduced number of presynaptic terminals, and upregulate dopa decarboxylase 66 . It follows that reduction of DAT might be the most sensitive marker of prodromal disease in the striatum, whilst loss of the ability to synthesise and store dopamine may be the critical factor that precipitates clinical motoric disease. Despite the histopathological differences that can occur between LRRK2-related and sporadic Parkinson's 67 , affected relatives in this kindred had PET imaging findings that were indistinguishable from those seen in sporadic disease. Larger studies in other prodromal cohorts using this multiple PET ligand approach will be valuable in determining its capacity to delineate prodromal Parkinson's and predict conversion more generally.
Subtle deficits on dopaminergic radiotracer imaging have been demonstrated in asymptomatic heterozygotes carrying one copy of the parkin mutation 68,69 -a rare cause of recessive familial Parkinson's -and it has been suggested that there may be an increased risk of Parkinson's in these subjects. However, despite the presence of mild motor signs in some cases, the imaging and clinical deficits do not appear to deteriorate significantly with time 70 . Furthermore, the pattern of striatal signal loss in homozygous individuals with parkinsonism is quite different from sporadic disease, with less sparing of the caudate nuclei 23 . A similar story is reported with PINK1 heterozygotes, another gene causing recessive Parkinson's; despite moderate group-level reductions in F-DOPA uptake and subtle motor signs, the risk of developing overt Parkinson's appears to be low 71 . These findings, as well as the scarcity of such subjects, make recessive heterozygotes less promising as pre-clinical cohorts.
Mutations in the glucocerebrocidase (GBA) gene, which cause the autosomal recessive lysosomal storage disorder Gaucher's disease, are one of the most prevalent genetic risk factors for Parkinson's disease 72 . Heterozygous GBA mutations occur in around 4-7% of sporadic cases and are 5 times more common in PD patients than in controls 73 .
However, despite evidence of a more severe non-motor prodrome in these patients 20 , the only study to conduct F-DOPA PET in non-PD heterozygous carriers found no evidence of signal loss in the striatum 74 . There was, however, reduced striatal F-DOPA uptake in a small
proportion of Gaucher's patients without Parkinsonism, potentially revealing a preparkinsonian disease state. On this evidence GBA heterozygotes in isolation are unlikely to be a useful pre-clinical cohort, but given the high frequency of GBA mutations the presence of these could potentially contribute to the risk stratification of population cohorts.
Imaging of the substantia nigra
Direct visualisation of the substantia nigra with neuroimaging has obvious appeal as a potential diagnostic approach given the specificity of degeneration in this area to parkinsonian disorders. Quantification of nigral tissue using cross-sectional imaging has been limited by the spatial resolution of these methods and the lack of sensitivity to detect subtle signal change in this area, though recent advances in MRI methodology have shown promise in overcoming these hurdles. Transcranial ultrasound on the other hand has been used for many years to image this key pathological area, and may have a role to play in preclinical risk stratification.
Transcranial sonography (TCS)
Transcranial ultrasound across the temporal bone can be used to directly visualise midbrain structures and qualitatively assess their echogenic properties. The key abnormality detected by this technique is increased echogenicity of the substantia nigra, which is consistently found in up to 90% of patients with Parkinson's disease [75] [76] [77] [78] ( figure 2 ). The origin of this signal is not fully understood but it has been shown to correlate with iron deposition 79 and microglia activation 80 Asian origin are an additional drawback 85 . Despite these limitations, it is a safe, inexpensive and non-invasive test which makes it a good candidate for screening large unselected cohorts.
TCS in population studies
In a study using TCS in a population-ascertained cohort of 1847 older persons, 17%
were found to have abnormal echogenicity of the substantia nigra 86 . After 5 years, 21
individuals had developed Parkinson's, of whom 78% had an abnormal baseline signal, making the risk of Parkinson's in those with an abnormal test 20 times higher than in those without 87 . The high prevalence of hyperechogenicity in the population and relatively low conversion rates limited the positive predictive value of the test to only 6.5% at 5 years, but this study nevertheless demonstrates the ability of TCS to substantially enrich cohorts for atrisk individuals.
TCS in REM sleep behaviour disorder (RBD)
Hyperechogenicity of the substantia nigra has been demonstrated in 35-50% of patients with idiopathic RBD, in keeping with the recognised prodromal risk status in these individuals [88] [89] [90] [91] . As with established Parkinson's, the signal does not change with time in RBD and its ability to predict pheno-conversion in longitudinal studies is disappointing 91 . Several studies have found no correlation in RBD subjects between substantia nigra hyperechogenicity and dopaminergic dysfunction measured by DAT or PET 54, 58, 92, 93 . These results further suggest that the TCS finding may be a binary susceptibility marker in RBD rather than a quantifiable measure of neurodegeneration. The combination of TCS and DAT SPECT was shown to be 100% sensitive for conversion from RBD to a parkinsonian disorder in one study 54 . Whilst this might provide some reassurance to those with normal imaging, the result is difficult to interpret given the lack of concordance between the two imaging modalities.
Interestingly, if the signal is truly static it ought to provide an estimate of the number of prodromal subjects in a given cohort, by comparing the rates of hyperechogenicity with those seen in Parkinson's and controls in the same centre. For example, Iwanami and colleagues 89 These observations suggest the sonographic findings are the result of a more widespread genetic risk profile and are unlikely to be a useful predictor of future pheno-conversion in this population. Again, the limitations in generalizability using genetically predisposed cohorts are illustrated by such studies.
MRI of the substantia nigra
Whilst MRI is commonly used in clinical practice as an adjunctive test in the differential diagnosis of parkinsonian syndromes, reliable identification of the specific neurodegenerative signature of idiopathic PD has not been possible with routine imaging sequences 42, 98 . However, the capacity to resolve the key brainstem structures and identify relevant pathological changes has improved with the advent of high field strength MRI scanners and sequences targeting specific molecular processes. Some of the most promising results come from direct imaging of the substantia nigra.
Diffusion tensor imaging (DTI) has been used to assess the integrity of nigrostriatal fibres in Parkinson's in a number of studies. Reduced fractional anisotropy in the substantia nigra in PD patients compared to controls is frequently reported 99 and reached significance in a recent meta-analysis 100 . However, there is substantial variation in results amongst DTI studies and as yet a consistent biomarker has not emerged that can accurately categorise individual patients 101 . Evidence in prodromal conditions is limited to a small number of studies in RBD, which have yielded similarly mixed results. Group level changes in diffusion parameters have been reported in the substantia nigra 102, 103 , but this is not a consistent finding 104, 105 . Much of the variation between studies is a result of methodological differences and it remains to be seen whether DTI can reliably detect early nigral degeneration once this technique is further refined.
More promising has been the finding that high field strength MRI with T2*-weighted sequences reveals a characteristic high signal area within the dorsolateral substantia nigra that is present in healthy controls and lost in patients with Parkinson's. A study comparing in vivo 7-Tesla MRI with post mortem MRI and histopathology found that this signal corresponds to the anatomical location of nigrosome 1, the nigral area that sustains maximal loss of dopaminergic neurons in Parkinson's 106 Only one study has investigated this sign in pre-clinical disease 109 . De Marzi and colleagues performed SWI sequences in 15 RBD subjects, 104 Parkinson's patients and 42
healthy controls. The dorsal nigral hyperintensity was absent in 92% of PD cases, and present in 97% of controls. 77% of RBD patients also had absence of the sign. Such a high rate in RBD patients may indicate that this sign develops early in the prodromal phase, or that it indicates a susceptibility trait in the same manner as TCS hyperechogenicity. Further studies in larger and more diverse prodromal cohorts with longitudinal follow-up will determine whether the signal can stratify patients according to their prodromal stage, but even if it is a trait marker, the low positivity observed in controls would make its predictive value greater than that of TCS. A limitation of this technique at present is that in 5-10% of cases the images are of insufficient quality for diagnostic assessment, usually due to motion artefacts.
Another disease specific target of MRI that has emerged recently is neuromelanin, a pigment expressed in high quantities in the substantia nigra and locus coeruleus 110 .
Neuromelanin is responsible for the for the dark colour of these structures and may Furthermore, changes in functional brain organisation can potentially reveal patterns that are more disease specific than structural abnormalities and may therefore be more predictive of future phenotype in prodromal cohorts 116 . Various imaging modalities have been applied to investigate network-level changes, measuring either metabolic activity, regional cerebral blood flow or changes in blood oxygenation. Most studies record these parameters in the resting state, avoiding the potential confounding factors in task-related imaging and therefore increasing their replicability and potential for translation into the clinical arena.
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Imaging networks through metabolism and perfusion
PET is commonly used to measure metabolic activity in the brain with the ligand 18 Ffluorodeoxyglucose (FDG). This gives a readout of cellular glucose uptake, which is physiologically most correlated to afferent synaptic activity and neuronal connectivity.
Patterns of brain perfusion have been investigated in pre-motor Parkinson's primarily with SPECT, using 99m Tc-Ethylene Cysteinate Dimer (ECD) as a marker of regional cerebral blood flow (rCBF). These two characteristics are not analogous, particularly in the context of medications that have vasoactive properties 116 ; nevertheless, consistent patterns of brain activity have been demonstrated using both modalities. More recently, the development of arterial spin labelled (ASL) MRI has enabled brain perfusion to be imaged non-invasively and without exposure to ionising radiation. ASL is limited by a relatively poor signal to noise ratio and its clinical potential remains somewhat uncertain, but it has demonstrated similar network patterns to PET and SPECT in established PD. 117, 118 The identification of a spatial covariance pattern specific to Parkinson's disease has been one of the most promising applications of network imaging techniques. This
Parkinson's Disease Related Pattern (PDRP) is detected using a principal component analysis (PCA)-based method known as the Scaled Subprofile Model (SSM). The approach, which is described in detail elsewhere 119 , involves the extraction of biologically relevant signals from pooled control and patient data using a whole brain multivariate analysis. The process is entirely data driven and as such it does not depend on a priori hypotheses regarding specific brain areas. The PDRP is characterised by increased activity in the pallido-thalamic and pontine regions with relative cortical reductions in the premotor, supplementary motor and parietal association areas 120 . It is highly reproducible within subjects and between populations 121, 122 and in established Parkinson's demonstrates progression over time and correlation with clinical severity measures 123, 124 . All of these factors make it a potentially valuable biomarker in clinical neuroprotective trials. Other network patterns have also been described in Parkinson's using this approach, which appear to reflect particular phenotypic features such as tremor and cognitive impairment 125, 126 .
Brain perfusion and metabolism in prodromal cohorts
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REM sleep behaviour disorder has been the focus of most of the studies to investigate metabolic and perfusion abnormalities in prodromal disease. Group level assessments of regional blood flow in RBD patients compared to controls have generated somewhat inconsistent results, but tend to show increased flow in subcortical regions, including the pons and putamen, and decreases in cortical areas 127, 128 . Clinical measures of cognition, olfaction and colour vision have been reported to correlate with decreased perfusion in the hippocampus, anterior parahippocampal gyrus and visual cortex respectively, suggesting that these perfusion measures have clinical relevance in prodromal disease 129, 130 . Decreases in rCBF over time have also been found with serial imaging of RBD patients, perhaps indicating a biomarker sensitive to progressive neurodegeneration 131 . A reproducible finding in RBD patients is increased perfusion in the hippocampus compared to controls, which is supported by the demonstration of a corresponding increase in metabolic activity in this region using FDG PET 130, 132, 133 . In one of the few longitudinal experiments to assess the predictive value of ECD SPECT, a larger increase in hippocampal perfusion was observed in 10 RBD patients who subsequently pheno-converted to parkinsonian disorders compared to 10 RBD patients who did not 132 .
Tang and colleagues investigated PDRP expression in a pseudo pre-motor situation by measuring the clinically unaffected hemisphere of early Parkinson's patients with unilateral signs 134 . They found increased PDRP expression in the 'asymptomatic'
hemisphere, which preceded the development of clinical disease in the contralateral limbs by 2 years. However, interpretation of this finding is limited by the fact that the PDRP signal was always symmetrical, which suggests that its expression on the 'unaffected' side may be attributable to contralateral basal ganglia degeneration.
Evidence that PDRP expression may be able to quantify the transition from prodromal to clinical Parkinson's is presented by Wu et al in a comparison of the network between RBD, Parkinson's and control subjects using FDG PET 135 . They found the PDRP to be expressed at intermediate levels in RBD subjects, significantly higher than in healthy controls but lower than patients with moderate PD. However, the increase in expression from RBD subjects to early stage Parkinson's did not reach significance. The authors also identified a distinct network in RBD subjects that was not present in controls and was expressed at lower levels in PD patients. They propose that this RBD related pattern is a marker of the prodromal phase of Parkinson's that decreases with the emergence of clinical
18 disease, though since they did not exclude the presence of RBD in their PD cohort the specific relationship of this pattern to RBD itself cannot be assessed. Further investigation with longitudinal follow-up will no doubt resolve this question.
One benefit of the PDRP as a biomarker is that it can differentiate idiopathic PD and DLB from other parkinsonian disorders such as MSA and PSP 136 , something that is not always possible with presynaptic dopaminergic radiotracer imaging 36 . This is important in the context of pre-motor disease as MSA in particular can exhibit a similar prodromal phenotype to Parkinson's disease. An intriguing recent study in RBD with considerable longitudinal follow up suggests that this distinction may be possible prior to the emergence of motoric disease 137 . Firstly, the presence of PDRP expression was confirmed in two RBD cohorts, using FDG PET and ECD SPECT respectively. The latter cohort was evaluated clinically after a 4.6-year mean follow-up period, during which 8 patients converted to either PD or dementia with Lewy Bodies (DLB). A logistic regression analysis combining baseline PDRP expression and age separated converters and non-converters into two distinct clusters. Further analysis of 3 RBD subjects who subsequently developed MSA showed that these formed a separate cluster using this model, which was largely accounted for by reduced PDRP expression compared to both non-converters and PD/DLB converters ( figure   4 ). The fact that converters to PD and DLB could not themselves be differentiated is unsurprising since these disorders likely represent a spectrum of common disease rather than truly distinct syndromes. It seems increasingly likely that pre-motor diagnosis will require a combination of both clinical and imaging biomarkers; this study provides encouraging evidence that the PDRP might contribute to such a model.
Functional MRI (fMRI) networks
Fluctuations in the resting brain's activity can be inferred from changes in the blood oxygen level dependent (BOLD) signal detected with appropriate T2*-sensitive MRI sequences 138 . Approaches to network characterisation generally involve either temporal correlation of this activity with a pre-defined region of interest or a data-driven approach, for example with independent component analysis (ICA) 139 . The functional connectivity networks that emerge closely mirror patterns of activation observed in task-based fMRI experiments 140 , suggesting that physiologically relevant interactions between brain regions
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19 can be probed in the resting state. Advantages of imaging brain connectivity with MRI are that such scans are short, non-invasive, free from ionising radiation and easy to acquire using widely-available hardware. Resting state functional MRI (rs-fMRI) can reveal perturbations of functional connectivity in neurodegenerative disorders in the absence of structural changes 141 , in some cases decades before the onset of clinical disease 142 ,
suggesting that these methods are sensitive to early pathogenic processes. 
Functional connectivity in genetic cohorts
Studies in asymptomatic LRRK2 mutation carriers have also revealed presymptomatic changes in brain network activity. Two task-based fMRI studies have demonstrated increases in effective connectivity between basal ganglia and cortical regions including the premotor cortex 152, 153 , perhaps suggestive of mechanisms compensating for early neurodegeneration. Increased task-related premotor cortex activity has also been reported in heterozygous carriers of the PINK1 and parkin mutations 154 . Resting state connectivity using a seed-based approach in 37 asymptomatic LRRK2 carriers revealed a shift in the pattern of connectivity between the right inferior parietal cortex (IPC) and the putamen 155 Despite this promise, some important obstacles remain to be overcome.
Reproducibility is a major issue and several of the methodologies described in this review require further replication in distinct populations. Translation of group level differences into meaningful individual results is also a challenge, and is limited by the relatively small sample size in many studies. Few of the studies discussed include longitudinal follow-up, something that will be crucial both to establish the change in imaging signals over time as well as to validate putative biomarkers against clinical outcomes.
All of the imaging methods studied thus far give a somewhat indirect readout of disease status rather than a specific quantification of the underlying pathological process.
This issue has led to problems in the study of other neurodegenerative diseases, particularly in the context of clinical trial design 157 , and given the fallibility of clinical diagnosis in up to 20% of Parkinson's disease cases 158 this is an important consideration. The development of a method to image alpha-synuclein directly would address this, but there remain significant methodological obstacles to doing so. Compared to beta-amyloid, which has been successfully imaged with PET in Alzheimer's disease, alpha-synuclein is far less abundant and is predominantly intracellular 159 . If these issues are overcome, however, in vivo visualisation of the key pathological protein in Parkinson's could prove an important marker of disease progression and response to alpha-synuclein targeted therapies.
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In the absence of a single diagnostic biomarker, the use of multimodal imaging also warrants further investigation. As well as providing a direct comparison of different imaging tools, the combination of these may yield more diagnostic information than either alone.
There is already some evidence that combining transcranial sonography and DAT SPECT in persons with RBD increases the sensitivity for future pheno-conversion 54 . Moreover, the sequential use of imaging tests may prove a more practical and cost effective way of screening cohorts for high-risk individuals 49 . Diagnostic algorithms that include clinical, genetic and molecular biomarkers in addition to imaging may have yet greater power to detect early disease. Such methods have been shown recently to have predictive value in subjects without evidence of dopaminergic dysfunction (SWEDDs) -individuals with parkinsonian signs but normal dopaminergic radiotracer imaging 160 .
Whichever imaging test ultimately proves most useful, methods of identifying at-risk individuals from the population to target with neuroimaging need to be both accurate and cost effective. Risk markers such as anosmia and constipation are not specific enough, whilst identification of RBD itself requires an invasive and costly diagnostic procedure. As recognition of RBD as an important clinical entity becomes more widespread, the development of new technologies to facilitate its diagnosis is clearly a priority. However, focusing solely on RBD will not capture the full spectrum of prodromal disease, and particularly neglects female patients. A more inclusive approach will require screening at the population level, which is likely to be a multi-stage process. To that end a set of new diagnostic criteria for prodromal Parkinson's proposed by the Movement Disorder Society may prove to be a valuable tool for large scale risk stratification 161 .
Alongside the advancement of imaging biomarkers must come improvements in the detection and quantification of clinical signs of parkinsonism. The current gold standard is the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) 162 , but whilst this is useful for the quantification of established PD it is likely to be insensitive to the progression of subtle motor signs in the prodromal phase and lacking in specificity in the elderly population 163 . The creation of precise, objective methods to quantify early motoric disease is another area where technology has great potential.
Finally, the advent of new diagnostic tools for pre-motor Parkinson's disease will only be worthwhile if effective disease modifying treatments become available. It is encouraging that trials of several re-purposed medications are currently underway in  High resolution MRI with sequences sensitive to iron and neuromelanin can detect the key pathological changes that occur in the substantia nigra of patients with Parkinson's and may have a role in pre-motor diagnosis.
 Analysis of resting state brain networks reveals Parkinson's related abnormalities in the prodromal phase which may be able to predict near-term conversion to motoric disease.
 Long term follow-up studies are required to validate use of these biomarkers in premotor disease.
